Evaluations of Biomarkers CDX1 and CDX2 in Gastric Cancer Prognosis - A Meta-analysis

Sep 21, 2026

Uploaded by Oliver

CDX1 and CDX2 are homeobox-type transcription factors proposed as biomarkers with prognostic relevance in intestinal-type gastric cancer, particularly in early disease before lymph node metastasis. This work connects CDX1/CDX2 findings with metabolic and epigenetic alterations involving IDH1/IDH2, suggesting potential personalized targeted therapies. A systematic review and meta-analysis of studies published from 1997 to December 2022 evaluated clinicopathologic correlations and survival outcomes. Twenty studies totaling 11,163 gastric cancer patients were included; CDX1 overexpression associated with improved overall survival, while CDX2 expression related to better 3- and 5-year survival.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages18

Reading Time45 min

AccessFree to download

Introduction

Background and rationale

Materials and methods

Aim and literature search strategy

Meta-analysis results

Prognostic associations (3-year and 5-year)

Discussion

Impact of IDH1/2 and CDX1/2 on prognosis and therapies

Evaluations of Biomarkers CDX1 and CDX2 in Gastric Cancer Prognosis: A Meta-analysis Azadeh Khayyat1*, Mohammad Ali Esmaeil Pour2, Olia Poursina3, Seyed Amir Zohouri4, Pragya Virendrakumar Jian1, Neel Patel5, Ami Amin3 1. Department of Pathology, Medical College of Wisconsin, WI, USA. 2. Department of Rheumatology, Medical College of Georgia at Augusta University, GA, USA. 3. Department of Pathology, Brown University, RI, USA. 4 . College student, Simon Fraser University, Department of Science, BC, Canada. 5. Department of Public Health, Icahn School of Medicine at Mount Sinai, NY, USA. | Article type: | ABSTRACT | | --- | --- | | Review Article | CDX1 and CDX2 are homeobox-type transcription factors that are potential biomarkers and | |
are associated with prognostic significance in intestinal-type gastric cancer early disease before | | |
lymph node metastasis is associated with better prognosis. In addition, the genes IDH 1 and | | |
IDH 2 previously known to be involved in brain cancer are implicated in cancer-related | | |
molecular signatures as a result new targeted personalized therapies may be possible. Our | | |
retrospective study determined the correlation between CDX markers and clinicopathologic | | |
data including survival in patients with gastric cancer. This study included studies from 1997 | | |
to December 2022 a meta-analysis to provide odds ratios (ORs) and relative risks (RRs) . We | | |
discussed in detail the impact of IDH 1/2 on the prognosis of gastric cancer outcomes and | | |
potential therapeutic strategies. Our meta-analysis included 20 studies identifying 11,163 | | |
patients with gastric cancer. We found that CDX 1 overexpression was associated with better | | |
overall survival (pooled HR: 1.28) and CDX 2 expression and better 3-year survival (pooled | | |
HR: 1.64) and 5-year survival was the pooled HR was correlated 1 94 with both showing | | | Received: | statistical correlation. Evidence suggests that IDH 1/2 mutations and CDX 1/2 overexpression | | 2024.01.16 | are closely associated with metabolic abnormalities epigenetic changes and mutations evidence | | Revised: | suggests the potential for novel targeted therapies in gastric cancer. CDX 1/2 overexpression | | 2024.05.14 | is associated with a favorable prognosis in gastric cancer cases. Further studies are needed to | | Accepted: | explore the clinical significance ofIDH 1/2 mutations and CDX 1/2 expression. | | 2024.05.29 | Keywords: Gastric cancer, CDX2, CDX1, IDH1, IDH2 prognosis, biomarker, stomach cancer | | Cite this article: Khayyat A, et al. Evaluations of Biomarkers CDX1 and CDX2 in Gastric Cancer Prognosis: A Meta-analysis. International Journal of Molecular and Cellular Medicine. 2024; 13(1):1-18 . DOI: 10.22088/IJMCM.BUMS.13.1.1 | | Introduction About 10,880 died of gastric cancer (6,490 men and 4,390 women) according to the American Cancer Society’s 2024 for stomach cancer in the United States. 1.5% of all new cancers diagnosed annually in the United States are gastric cancer. 26,890 new cases of gastric cancer (16,160 in men and 10,730 in women) were estimated (1) . Based on data from 2017–2019, about 0.8 percent of men and women will be newly diagnosed with stomach cancer in their lifespan (2) . The need for early diagnosis and informed therapy is critical, with a focus on innovative biomarkers. For instance, patients without distant nodal metastasis generally have a favorable prognosis (3), highlighting the early diagnosis importance. The caudal-related homeobox gene family's CDX1 and CDX2 are important players in the initiation and spread of stomach cancer (4,5) . These elements might be employed as biomarkers since they are required for developing intestinal epithelial cells and because there is evidence connecting their expression to stomach cancer. While CDX2 expression is associated with better differentiation and reduced lym

FAQs

What roles do CDX1 and CDX2 play as biomarkers in gastric cancer prognosis?

CDX1 and CDX2 are homeobox-type transcription factors linked to prognostic significance in intestinal-type gastric cancer. CDX1 overexpression and CDX2 expression are associated with improved survival outcomes in the meta-analysis.

How was the literature search conducted and what time range was included?

Databases including PubMed, MEDLINE, Cochrane, and EMBASE were searched from the earliest possible date through May 1, 2023, and included studies published from 1997 to December 2022 in the meta-analysis.

How do IDH1 and IDH2 relate to the prognosis of gastric cancer in this study?

The study highlights IDH1/IDH2 as part of molecular signatures connected with metabolic abnormalities and epigenetic changes. It discusses how IDH1/2 may influence prognosis and could support novel targeted therapy strategies.

Sep 21, 2026

Uploaded by Oliver